Table 2.
Demographic, clinical, histological, molecular and treatment characteristics of patients and analysis of groups homogeneity (test Pearson Khi2)
| Characteristic | Group A [n = 110] No (%) | Group B [n = 134] No (%) | p value |
| Age | |||
| <40 | 31 (28.2%) | 23 (17.2%) | 0.039 |
| ≥40 | 79 (71.8%) | 111 (82.8%) | |
| Menopausal status | |||
| No | 75 (72.8%) | 77 (62.1%) | 0.087 |
| Yes | 28 (27.2%) | 47 (37.9%) | |
| Side | |||
| Right | 48 (43.6%) | 71 (53%) | 0.146 |
| Left | 62 (56.4%) | 63 (47%) | |
| Surgery | |||
| Mastectomy (Patey or Halsted) | 89 (80.9%) | 116 (86.6%) | 0.23 |
| Conservative | 21 (19.1%) | 18 (13.4%) | |
| Histology | |||
| DIC | 99 (94,3%) | 120 (90,9%) | 0.33 |
| LIC | 6 (5.7%) | 12 (9.1%) | |
| SBR | |||
| I | 6 (5.7%) | 11 (8.5%) | 0.567 |
| II | 69 (65.1%) | 87 (66.9%) | |
| III | 31 (29.2%) | 32 (24.6%) | |
| Hormonal receptors | |||
| ER | |||
| Positive | 77 (72%) | 97 (73.5%) | 0.793 |
| Negative | 30 (28%) | 35 (26.5%) | |
| PR | |||
| Positive | 61 (57.5%) | 82 (62.1%) | 0.474 |
| Negative | 45 (42.5%) | 50 (37.9%) | |
| Tumour | |||
| pT1 | 16 (14.7%) | 19 (14.5%) | 0.732 |
| pT2 | 62 (56.9%) | 76 (58%) | |
| pT3 | 28 (25.7%) | 29 (22.1%) | |
| pT4 | 3 (2.8%) | 7 (5.3%) | |
| pN, axillary | |||
| pN0 | 20 (18.2%) | 40 (29.9%) | 0.001 |
| pN1 | 30 (27.3%) | 42 (31.3%) | |
| pN2 | 31 (28.2%) | 42 (31.3%) | |
| pN3 | 29 (26.4%) | 10 (7.5%) | |
| Breast/thoracic wall irradiation | |||
| Yes | 109 (99.1%) | 124 (92.5%) | 0.014 |
| No | 1 (0.9%) | 10 (7.5%) | |
| Prophylactic supraclavicular fossa radiotherapy | |||
| Yes | 104 (94.5%) | 127 (94.8%) | 0.936 |
| No | 6 (5.5%) | 7 (5.2%) | |
| Internal mammary radiotherapy | |||
| Yes | 105 (95.5%) | 128 (95.5%) | 0.98 |
| No | 5 (4.5%) | 6 (4.5%) | |
| Axillary radiotherapy | |||
| Yes | 18 (16.4%) | 31 (23.1%) | 0.189 |
| No | 92 (83.6%) | 103 (76.9%) | |
SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptor